Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Tumor bed proton irradiation in young children with localized medulloblastoma.

Grewal AS, Li Y, Fisher MJ, Minturn J, Paltin I, Belasco J, Phillips P, Kang T, Lustig RA, Hill-Kayser C.

Pediatr Blood Cancer. 2019 Sep 12:e27972. doi: 10.1002/pbc.27972. [Epub ahead of print]

PMID:
31512390
2.

A prospective clinical trial of proton therapy for chordoma and chondrosarcoma: Feasibility assessment.

Baumann BC, Lustig RA, Mazzoni S, Grady SM, O'Malley BW, Lee JYK, Newman JG, Schuster JM, Both S, Lin A, Dorsey JF, Alonso-Basanta M.

J Surg Oncol. 2019 Aug;120(2):200-205. doi: 10.1002/jso.25502. Epub 2019 May 20.

PMID:
31111502
3.

Emergent Radiation for Leukemic Optic Nerve Infiltration in a Child Receiving Intrathecal Methotrexate.

LaRiviere MJ, Avery RA, Dolan JG, Adamson PC, Zarnow DM, Xie Y, Avery SM, Kurtz GA, Hill-Kayser CE, Lustig RA, Lukens JN.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):226-230. doi: 10.1016/j.prro.2019.04.004. Epub 2019 Apr 9. No abstract available.

PMID:
30978466
4.

Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.

Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, Balamuth N, Womer R, Mattei P, Grupp S, Mosse YP, Maris JM, Bagatell R.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):401-408. doi: 10.1016/j.ijrobp.2019.01.095. Epub 2019 Feb 7.

PMID:
30738983
5.

The Promise of Proton Therapy for Central Nervous System Malignancies.

Vogel J, Carmona R, Ainsley CG, Lustig RA.

Neurosurgery. 2019 May 1;84(5):1000-1010. doi: 10.1093/neuros/nyy454.

PMID:
30476191
6.

Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.

Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, O'Rourke DM, Brem S, Desai AS, Nasrallah MP.

J Neurooncol. 2019 Jan;141(2):421-429. doi: 10.1007/s11060-018-03050-6. Epub 2018 Nov 16.

PMID:
30446903
7.

Circulating Glioma Cells Exhibit Stem Cell-like Properties.

Liu T, Xu H, Huang M, Ma W, Saxena D, Lustig RA, Alonso-Basanta M, Zhang Z, O'Rourke DM, Zhang L, Gong Y, Kao GD, Dorsey JF, Fan Y.

Cancer Res. 2018 Dec 1;78(23):6632-6642. doi: 10.1158/0008-5472.CAN-18-0650. Epub 2018 Oct 15.

PMID:
30322863
8.

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.

Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, Davuluri RV, Lustig RA, Dahmane N, Bilello M, O'Rourke DM, Davatzikos C.

Sci Rep. 2018 Mar 23;8(1):5087. doi: 10.1038/s41598-018-22739-2.

9.

Prompt Gamma Imaging for In Vivo Range Verification of Pencil Beam Scanning Proton Therapy.

Xie Y, Bentefour EH, Janssens G, Smeets J, Vander Stappen F, Hotoiu L, Yin L, Dolney D, Avery S, O'Grady F, Prieels D, McDonough J, Solberg TD, Lustig RA, Lin A, Teo BK.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):210-218. doi: 10.1016/j.ijrobp.2017.04.027. Epub 2017 May 3.

PMID:
28816148
10.

Neuroplastic Response After Radiation Therapy for Pediatric Brain Tumors: A Pilot Study.

Armstrong CL, Fisher MJ, Li Y, Lustig RA, Belasco JB, Minturn JE, Hill-Kayser CE, Batra S, Phillips PC.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):991-998. doi: 10.1016/j.ijrobp.2016.01.013. Epub 2016 Mar 17.

PMID:
27302514
11.

Impact of image guidance during whole-brain radiation therapy.

Ojerholm E, Anderson N, Patel K, Wang P, Lustig RA, Alonso-Basanta M, Kurtz G, Jones JA.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e345-e351. doi: 10.1016/j.prro.2016.03.006. Epub 2016 Mar 19.

PMID:
27156423
12.

Patterns of Failure for Pediatric Glioblastoma Multiforme Following Radiation Therapy.

Shabason JE, Sutton D, Kenton O, Guttmann DM, Lustig RA, Hill-Kayser C.

Pediatr Blood Cancer. 2016 Aug;63(8):1465-7. doi: 10.1002/pbc.26031. Epub 2016 Apr 29.

PMID:
27128519
13.

Effects of full-neck volumetric-modulated arc therapy vs split-field intensity-modulated head and neck radiation therapy on low neck targets and structures.

Anamalayil SJ, Teo BK, Lin A, Lustig RA, Ahn PH.

Br J Radiol. 2016 Jun;89(1062):20160009. doi: 10.1259/bjr.20160009. Epub 2016 Apr 4.

14.

Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.

Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.

J Neurooncol. 2016 Apr;127(2):391-400. doi: 10.1007/s11060-015-2051-3. Epub 2016 Jan 8.

15.

Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.

Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, Lustig RA, Brem S, Mohan S, Wolf RL, Desai A, Poptani H.

AJNR Am J Neuroradiol. 2016 Jan;37(1):28-36. doi: 10.3174/ajnr.A4474. Epub 2015 Oct 8.

16.

Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting system.

Hill-Kayser CE, Gabriel P, Volz E, Lustig RA, Tochner Z, Hahn SM, Maity A.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e417-e422. doi: 10.1016/j.prro.2015.06.001. Epub 2015 Jul 26.

PMID:
26215584
17.

Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients.

Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM.

Transl Oncol. 2014 Dec;7(6):752-8. doi: 10.1016/j.tranon.2014.10.004.

18.

Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.

Ojerholm E, Lee JY, Thawani JP, Miller D, O'Rourke DM, Dorsey JF, Geiger GA, Nagda S, Kolker JD, Lustig RA, Alonso-Basanta M.

J Neurosurg. 2014 Dec;121 Suppl:75-83. doi: 10.3171/2014.6.GKS14708.

PMID:
25434940
19.

Supine craniospinal irradiation using a proton pencil beam scanning technique without match line changes for field junctions.

Lin H, Ding X, Kirk M, Liu H, Zhai H, Hill-Kayser CE, Lustig RA, Tochner Z, Both S, McDonough J.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):71-8. doi: 10.1016/j.ijrobp.2014.05.029. Epub 2014 Jul 12.

PMID:
25028286
20.

Preserving Fertility in Adolescent Girls and Young Women Requiring Craniospinal Irradiation: A Case Report and Discussion of Options to Be Considered Prior to Treatment.

Lester-Coll NH, Morse CB, Zhai HA, Both S, Ginsberg JP, Gracia CR, Lustig RA, Tochner Z, Hill-Kayser CE.

J Adolesc Young Adult Oncol. 2014 Jun 1;3(2):96-99.

21.

The effects of titanium mesh on passive-scattering proton dose.

Lin H, Ding X, Yin L, Zhai H, Liu H, Kassaee A, Hill-Kayser C, Lustig RA, McDonough J, Both S.

Phys Med Biol. 2014 May 21;59(10):N81-9. doi: 10.1088/0031-9155/59/10/N81. Epub 2014 Apr 28.

PMID:
24778368
22.

Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.

Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, Wileyto EP, Hahn SM, Dorsey JF.

Cancer Res. 2014 Apr 15;74(8):2152-9. doi: 10.1158/0008-5472.CAN-13-0813. Epub 2014 Feb 13.

23.

A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.

Alonso-Basanta M, Fang P, Maity A, Hahn SM, Lustig RA, Dorsey JF.

J Neurooncol. 2014 Jan;116(2):365-372. doi: 10.1007/s11060-013-1303-3. Epub 2013 Nov 6.

24.

Acute toxicity of proton beam radiation for pediatric central nervous system malignancies.

Suneja G, Poorvu PD, Hill-Kayser C, Lustig RA.

Pediatr Blood Cancer. 2013 Sep;60(9):1431-6. doi: 10.1002/pbc.24554. Epub 2013 Apr 22.

PMID:
23610011
25.

Headache as a risk factor for neurovascular events in pediatric brain tumor patients.

Kranick SM, Campen CJ, Kasner SE, Kessler SK, Zimmerman RA, Lustig RA, Phillips PC, Beslow LA, Ichord R, Fisher MJ.

Neurology. 2013 Apr 16;80(16):1452-6. doi: 10.1212/WNL.0b013e31828cf81e. Epub 2013 Mar 13.

26.

Acute toxicity profile of patients with low-grade gliomas and meningiomas receiving proton therapy.

Maquilan G, Grover S, Alonso-Basanta M, Lustig RA.

Am J Clin Oncol. 2014 Oct;37(5):438-43. doi: 10.1097/COC.0b013e31827de86b.

PMID:
23388559
27.

Commentary: navigating a data desert: cochrane leaves the question of intracystic bleomycin unanswered in craniopharyngioma.

Plastaras JP, Lustig RA, Hill-Kayser CE.

Neurosurgery. 2012 Nov;71(5):E1062-3. doi: 10.1227/NEU.0b013e31826d7c68. No abstract available.

PMID:
22902335
28.

Phase measurement of cognitive impairment specific to radiotherapy.

Armstrong CL, Shera DM, Lustig RA, Phillips PC.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e319-24. doi: 10.1016/j.ijrobp.2011.12.083. Epub 2012 Mar 13.

29.

A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS.

Clin Cancer Res. 2012 Mar 1;18(5):1435-46. doi: 10.1158/1078-0432.CCR-11-1951. Epub 2012 Jan 18. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3781.

30.

Proton beam therapy in skull base pathology.

Alonso-Basanta M, Lustig RA, Kennedy DW.

Otolaryngol Clin North Am. 2011 Oct;44(5):1173-83. doi: 10.1016/j.otc.2011.08.012. Review.

PMID:
21978900
31.

The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study.

Evans SM, Jenkins KW, Chen HI, Jenkins WT, Judy KD, Hwang WT, Lustig RA, Judkins AR, Grady MS, Hahn SM, Koch CJ.

Transl Oncol. 2010 Jun 1;3(3):160-9.

32.

Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck.

Shinohara ET, Maity A, Jha N, Lustig RA.

Head Neck. 2009 Mar;31(3):406-11. doi: 10.1002/hed.20898.

33.

A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer.

Kujundzić M, Vogl TJ, Stimac D, Rustemović N, Hsi RA, Roh M, Katicić M, Cuenca R, Lustig RA, Wang S.

J Surg Oncol. 2007 Nov 1;96(6):518-24.

PMID:
17671969
34.

Imaging response in malignant glioma, RTOG 90-06.

Lustig RA, Seiferheld W, Berkey B, Yung AW, Scarantino C, Movsas B, Jones CU, Simpson JR, Fishbach J, Curran WJ Jr.

Am J Clin Oncol. 2007 Feb;30(1):32-7.

PMID:
17278892
35.

Recurrent late cerebral necrosis with aggressive characteristics after radiosurgical treatment of an arteriovenous malformation. Case report.

Chen HI, Burnett MG, Huse JT, Lustig RA, Bagley LJ, Zager EL.

J Neurosurg. 2006 Sep;105(3):455-60.

PMID:
16961142
36.

Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer.

Elmariah SB, Huse J, Mason B, Leroux P, Lustig RA.

Breast J. 2006 Sep-Oct;12(5):470-4.

PMID:
16958968
37.

Hypoxia is important in the biology and aggression of human glial brain tumors.

Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, Grady MS, Koch CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8177-84.

38.

Does stereotactic eligibility for the treatment of glioblastoma cause selection bias in randomized studies?

Lustig RA, Scott CB, Curran WJ.

Am J Clin Oncol. 2004 Oct;27(5):516-21.

PMID:
15596923
39.

A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors.

Lustig RA, Vogl TJ, Fromm D, Cuenca R, Alex Hsi R, D'Cruz AK, Krajina Z, Turić M, Singhal A, Chen JC.

Cancer. 2003 Oct 15;98(8):1767-71.

40.

Light Dosimetry at Tissue Surfaces for Small Circular Fields.

Zhu TC, Dimofte A, Hahn SM, Lustig RA.

Proc SPIE Int Soc Opt Eng. 2003 Jun 12;4952:56-67.

41.

Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement.

McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO.

Clin Infect Dis. 2003 Mar 15;36(6):759-65. Epub 2003 Mar 6.

PMID:
12627360
42.

In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.

Dimofte A, Zhu TC, Hahn SM, Lustig RA.

Lasers Surg Med. 2002;31(5):305-12.

PMID:
12430147
43.

Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: a preliminary report.

DeNittis AS, Stambaugh MD, Lang P, Wallner PE, Lustig RA, Dillman RO, Order SE.

Am J Clin Oncol. 1999 Aug;22(4):355-60.

PMID:
10440189
44.

Changes in high-dose-rate tandem and ovoid applicator positions during treatment in an unfixed brachytherapy system.

Pham HT, Chen Y, Rouby E, Lustig RA, Wallner PE.

Radiology. 1998 Feb;206(2):525-31.

PMID:
9457208
45.

A new method for delivering radioactive cytotoxic agents in solid cancers.

Order SE, Siegel JA, Lustig RA, Principato R, Zeiger LS, Johnson E, Zhang H, Lang P, Pilchik NB, Metz J, et al.

Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):715-20.

PMID:
7928505
46.

Improvements observed in care and outcome in carcinoma of the larynx.

Lustig RA, Krall JM, Curran WJ, Hanks GE.

Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):101-4.

PMID:
1993619
47.

Effect of Fluosol-DA 20% and oxygen on response of C57BL/6 mice to whole-body irradiation.

Waldow SM, Lustig RA, Brass-Marlow EL, Nunno MP, Holst RJ, Wallner PE.

Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):665-8.

PMID:
2211213
48.

Impact of initial quality control review on study outcome in lung and head/neck cancer studies--review of the Radiation Therapy Oncology Group experience.

Wallner PE, Lustig RA, Pajak TF, Robinson G, Davis LW, Perez CA, Seydel HG, Marcial VA, Laramore GE.

Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):893-900. Review.

PMID:
2674086
49.

The effect of fraction size on control of early glottic cancer.

Schwaibold F, Scariato A, Nunno M, Wallner PE, Lustig RA, Rouby E, Gorshein D, Wenger J.

Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):451-4.

PMID:
3343152
50.

Fluosol DA and oxygen as an adjuvant to the radiotherapeutic management of advanced head/neck carcinoma.

Lustig RA, Rose CM, McIntosh-Lowe NL.

Biomater Artif Cells Artif Organs. 1988;16(1-3):511-8. No abstract available.

PMID:
3179488

Supplemental Content

Loading ...
Support Center